Introduction
============

Invasive candidiasis, caused by the yeast *Candida,* is one of the most common opportunistic fungal infections worldwide ([@R1],[@R2]). Invasive candidiasis includes, among other manifestations, intra-abdominal infections, osteomyelitis, and bloodstream infections (candidemia), with candidemia being the most common type of invasive candidiasis. In the United States and elsewhere, *Candida* species are a leading cause of health care--associated bloodstream infections ([@R3]--[@R5]). Candidemia is associated with prolonged hospitalizations, high health care costs, substantial morbidity, and all-cause in-hospital mortality of up to 30% ([@R6]).

*Candida* is a common commensal organism of the gastrointestinal tract and can live on skin ([@R7]). Disruption of the normal barriers provided by the gastrointestinal tract or skin can lead to invasive infections (i.e., autoinfection). Overgrowth and translocation into the bloodstream can occur under the stressful physiologic conditions that generally occur during long-term hospitalizations and intensive care unit (ICU) stays. Recent abdominal surgery and other medical interventions, disruption of the microbiome from antibiotics, receipt of total parental nutrition (TPN), diabetes, malignancies, neutropenia, use of immunosuppressive therapies, and presence of indwelling catheters such as central venous catheters (CVCs) and other devices ([@R8]--[@R10]) are all risk factors for candidemia. Premature newborns with indwelling catheters also are at increased risk for candidemia ([@R11]--[@R13]). In addition to autoinfection, infections with certain species of *Candida*, particularly *Candida auris* and *Candida parapsilosis*, can result from transmission between patients in health care settings ([@R14]).

Underlying conditions that contribute to candidemia have changed over time as guidelines and practices for prophylactic antifungal therapy and CVC care have changed. For example, antifungal prophylaxis is now routinely used for extremely premature newborns in some neonatal units and for patients with certain types of hematologic malignancies, dramatically reducing rates of candidemia in these populations ([@R15],[@R16]).

A few hundred species of *Candida* exist, a small proportion of which causes nearly all invasive infections in humans. *Candida albicans* is the most common species that causes candidiasis in the United States ([@R1]); however, the proportion of infections caused by species other than *C. albicans*, such as *Candida glabrata* and *C. parapsilosis*, has grown in the last few decades ([@R17]). These species exhibit higher levels of resistance to antifungal medications and might be associated with higher mortality than *C. albicans* ([@R18]). Recent reports indicate an increase in multidrug-resistant *C. glabrata* isolates in the United States ([@R19],[@R20]). Equally concerning are newly emerging species of *Candida*, such as *C. auris*, which was first described in 2009 ([@R21]) and has since been reported in approximately 30 countries, including the United States ([@R22]). *C. auris* is resistant to multiple drugs and has caused large health care--associated outbreaks, spreading readily within certain health care facilities and creating a worldwide public health threat ([@R14]).

The incidence of candidemia in the United States has been measured periodically in different regions and populations. Incidence increased fivefold during 1980--1990, according to surveillance conducted as part of the National Nosocomial Infections Surveillance (NNIS) system ([@R23],[@R24]). The incidence of candidemia started to decrease in the mid-1990s through the mid-2000s among low birthweight newborns, in part because of recommendations for fluconazole prophylaxis in certain settings ([@R25]--[@R27]). In population-based surveillance performed in the metropolitan areas of Atlanta, Georgia, and Baltimore, Maryland, candidemia incidence (primarily among adults) increased 10%--40% from the early 1990s and the late 2000s, which was followed by more recent reports of decreases in these areas ([@R6],[@R28]--[@R30]).

Because of these changes, monitoring candidemia incidence in various populations, characterizing the distribution of species causing candidemia, estimating the prevalence of antifungal drug resistance, and determining whether risk factors, treatment, and outcomes for candidemia have changed over time are important. However, candidemia is not required to be reported in most states and is not a nationally notifiable disease, with the exception of *C. auris* infections ([@R31]), which are a small percentage of candidemia cases in the United States. Candidemia surveillance conducted through CDC's Emerging Infections Program (EIP), a collaboration among CDC, state health departments, and academic partners that was initiated in 1995, is the only source of population-based information on candidemia in the United States ([@R32]). EIP surveillance for candidemia started in two sites (in Georgia and Maryland) in 2008 and expanded to two more sites (in Oregon and Tennessee) in 2011. This report includes 2012--2016 data from all four sites. The findings can be used by health care providers, infection control practitioners, stakeholders in the health care industry, and public health officials at federal, state, and local levels to promote awareness of candidemia incidence, risk factors, and outcome and to inform prevention measures.

Methods
=======

Data Source
-----------

During 2012--2016, CDC's EIP ([@R32]) conducted active population-based surveillance for culture-confirmed candidemia in four sites: Georgia (eight counties in the metropolitan Atlanta area, with a 2014 population of 3.93 million), Maryland (city of Baltimore and Baltimore County, with a 2014 population of 1.45 million), Oregon (Portland tricounty area, with a 2014 population of 1.73 million), and Tennessee (nine counties surrounding Knoxville in East Tennessee, with a 2014 population of 943,000). The combined population under surveillance was approximately 8.06 million persons, representing approximately 2.5% of the U.S. population in 2014.

Surveillance Case Definition
----------------------------

A case of candidemia was defined as a blood culture positive for a *Candida* species collected from a resident of the surveillance area during 2012--2016. An episode was defined as the 30-day period after the initial culture was positive. A new culture that was positive after the 30-day period was counted as a different case in the same patient. Any blood cultures positive for a *Candida* species within 30 days of the initial positive culture from the same patient were considered part of the same case, or episode, including different *Candida* species identified within the 30-day period or multiple *Candida* species found on the date of initial positive culture. The date of candidemia refers to the date the initial blood culture that yielded *Candida* was collected. Unless specified, data are presented at the case level because each of the measured exposure variables (e.g., time from hospital admission to culture) can change from case to case in the same person. However, demographic data are at the patient level because characteristics such as sex and race do not change from case to case in the same person.

Data Collection
---------------

Clinical, reference, and commercial laboratories that serve the population in the surveillance catchment areas were recruited to participate in the surveillance program and report cases of candidemia to the local surveillance officer. Once notified of a positive *Candida* blood culture, surveillance officers from each site used the surveillance case definition to determine case status and completed a standardized case report form to gather demographic and clinical data from the medical record. Surveillance officers received detailed instructions on completing the abstraction form and training in chart abstraction. In addition, surveillance officers performed periodic audits of laboratory microbiology records to ensure completeness of reporting. The corresponding *Candida* species isolates were sent to CDC for species confirmation and antifungal susceptibility testing. Deidentified data were sent to CDC.

Variables Assessed
------------------

The chart review and case report forms used to collect data are available (2010--2013 long chart review form, <https://stacks.cdc.gov/view/cdc/80195>; 2010--2013 short chart review form, <https://stacks.cdc.gov/view/cdc/80196>; 2014 case report form, <https://stacks.cdc.gov/view/cdc/80193>; and 2016 case report form, <https://stacks.cdc.gov/view/cdc/80194>). The forms include information on demographic data, including age at time of positive culture, sex, and race. Adults were defined as patients aged \>18 years. Other variables collected from medical chart review included underlying medical conditions and medical comorbidities; dates of hospital admission and discharge; receipt of antibiotics and antifungal medications; TPN in the 14 days before candidemia diagnosis; presence of a CVC within 2 days before diagnosis; treatment received for candidemia; and patient outcome (i.e., hospital discharge or death).

A candidemia case was defined as a health care--onset case when the initial positive *Candida* culture was obtained ≥3 days after admission; as a health care--associated community-onset case when the culture was obtained \<3 days after admission for a patient with a recent health care exposure; or as a community-onset case when the culture was obtained \<3 days after admission for a patient without a recent health care exposure. Recent health care exposure was defined as one or more of the following: residence in a nursing home, hospitalization in the 90 days before date of candidemia, or receipt of hemodialysis.

Laboratory Methods
------------------

At CDC's fungal reference laboratory, *Candida* species identification from isolates obtained from blood during 2012--2014 was performed using a Luminex assay or DNA sequencing of the D1/D2 subunit of the 28S ribosomal DNA (rDNA) ([@R33]). During 2015--2016, matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) ([@R34]) was used for species identification. Antifungal susceptibility testing was performed at CDC with custom prepared microdilution plates (Trek Diagnostics) for fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 document guidelines ([@R35]). Growth was observed after 24 hours, and the minimum inhibitory concentration was determined by the lowest concentration of drug in which growth was decreased by approximately 50% compared with the control well. Isolates were categorized as resistant to each drug using the 2012 CLSI M27-S4 species-specific breakpoints ([@R36]). Amphotericin B susceptibility was tested using Etest strips (bioMérieux) according to the manufacturer's instructions.

Analysis
--------

Crude candidemia incidence rates per 100,000 population are presented for each site by year. Percentages and age-, sex-, and race-specific incidence rates are presented for demographic characteristics of patients with candidemia during 2012--2016. Denominators used to calculate incidence rates for each surveillance site or demographic characteristic were obtained from the U.S. Census Bureau population and housing unit estimates for the corresponding years ([@R37]). A multivariable negative binomial regression model was used to assess adjusted incidence rate ratios across demographic factors (age, sex, and race) and surveillance sites (state). Chi-square tests were performed to assess the difference in proportions across two groups, and univariable negative binomial regression models were used to assess trends in the candidemia incidence rate over the 5-year surveillance period. Interaction terms between the variables in the model were examined. The tests were conducted at significance level of α = 0.05. SAS was used to perform the statistical analyses (version 9.4; SAS Institute).

Ethical Review
--------------

CDC conducted ethical review of this surveillance activity and classified it as a nonresearch public health activity. This activity also was evaluated individually at each participating surveillance site and determined to be nonresearch in Georgia and Oregon and exempt research in Maryland. In Tennessee, the site received expedited approval from a local hospital review board, and other hospitals determined the surveillance activity to be nonresearch.

Results
=======

Demographic Characteristics and Incidence
-----------------------------------------

During 2012--2016, a total of 3,492 candidemia cases were identified from 3,235 patients. The median age of patients with candidemia was 59 years (interquartile range \[IQR\]: 45--71 years). Thirty-eight percent of patients were aged 45--64 years, and 37% were aged ≥65 years; infants aged \<1 year represented 2% of cases ([Table 1](#T1){ref-type="table"}). Fifty-two percent were male, 45% were black, and 49% were nonblack (includes white patients, Asian patients \[2%\], and American Indian/Alaska Native patients \[\<0.05%\]); race was unknown for 7%. A higher proportion of patients in Georgia and Maryland were black (56% and 59%, respectively) compared with Oregon (7%) and Tennessee (8%).

###### Demographic characteristics of patients with candidemia --- four sites, United States, 2012--2016

  Characteristic                     Georgia       Maryland      Oregon        Tennessee     Total
  ---------------------------------- ------------- ------------- ------------- ------------- ---------------------
  Median age (median, IQR)           60 (46--71)   60 (47--72)   57 (40--68)   58 (43--72)   **59 (45**--**71)**
  **Age group, yrs\***               **No. (%)**   **No. (%)**   **No. (%)**   **No. (%)**   **No. (%)**
  Infant (\<1)                       44 (3)        28 (3)        3 (1)         4 (1)         **79 (2)**
  1--18                              53 (4)        24 (3)        14 (4)        4 (1)         **95 (3)**
  19--44                             259 (17)      162 (18)      82 (25)       129 (27)      **632 (20)**
  45--64                             598 (40)      345 (38)      133 (40)      154 (32)      **1,230 (38)**
  ≥65                                554 (37)      359 (39)      102 (31)      182 (38)      **1,197 (37)**
  **Sex^†^**                                                                                 
  Male                               786 (52)      507 (55)      162 (49)      234 (49)      **1,689 (52)**
  **Race^§^**                                                                                
  Black                              843 (56)      539 (59)      25 (7)        36 (8)        **1,443 (45)**
  White                              518 (34)      337 (37)      234 (70)      421 (89)      **1,510 (47)**
  American Indian/Alaska Native      2 (0)         3 (0)         6 (2)         0 (0)         **11 (0)**
  Asian                              34 (2)        9 (1)         10 (3)        3 (1)         **56 (2)**
  Native Hawaiian/Pacific Islander   2 (0)         0 (0)         1 (0)         0 (0)         **3 (0)**

**Abbreviation:** IQR = interquartile range.

\* Unknown: n = 2.

^†^ Unknown: n = 16.

^§^ Unknown: n = 212 (7%).

The crude candidemia incidence averaged across sites and years was 8.7 per 100,000 population (range: 8.3--9.1) during 2012--2016 ([Figure 1](#F1){ref-type="fig"}). The crude annual incidence differed by site, with the highest in Maryland (14.1 per 100,000 population) and lowest in Oregon (4.0 per 100,000 population). Adjusting for age, sex, and race, the incidence rate ratio in Maryland was 2.4 (95% confidence interval \[CI\]: 2.0--2.8) times the incidence in Oregon.

![Crude annual candidemia incidence\* --- four sites, United States, 2012--2016\
\* Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years.](ss6808a1-f1){#F1}

The crude incidence of candidemia also varied by age group, with the highest crude incidence among adults aged ≥65 years (25.5 per 100,000), followed by infants aged \<1 year (15.8 per 100,000). The lowest crude incidence occurred among persons aged 1--18 years (1.1 per 100,000) ([Figure 2](#F2){ref-type="fig"}). Adjusting for sex, race, and site, the incidence rate ratio among adults aged ≥65 years was 24.2 (95% CI: 19.5--30.0) times the incidence among persons aged 1--18 years.

![Crude annual candidemia incidence,\* by age --- four sites,^†^ United States, 2012--2016\
\* Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years.\
^†^ Georgia, Maryland, Oregon, and Tennessee.](ss6808a1-f2){#F2}

The crude incidence among males (9.4 per 100,000) was higher than among females (8.0 per 100,000) ([Figure 3](#F3){ref-type="fig"}). Adjusting for age, race, and site, the candidemia incidence rate ratio among males was 1.3 (95% CI: 1.2--1.4) times the rate among females. The adjusted incidence ratio was 1.6 (95% CI: 1.2--2.3) times higher among adults aged ≥65 years.

![Crude annual candidemia incidence,\* by sex --- four sites,^†^ United States, 2012--2016\
\* Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years.\
^†^ Georgia, Maryland, Oregon, and Tennessee.](ss6808a1-f3){#F3}

The crude incidence among blacks was higher than among nonblacks (13.7 versus 5.8 per 100,000) ([Figure 4](#F4){ref-type="fig"}). Adjusting for sex, age, and site, the incidence rate ratio among blacks was 2.3 (95% CI: 2.1‒2.6) times the incidence among nonblacks. The disparity in incidence by race existed across all age groups, with the adjusted incidence rate ratio ranging from 2.1 (95% CI: 1.6--2.6) times the incidence among blacks compared with nonblacks among adults aged 19--44 years to 3.1 (95% CI: 2.1--4.6) times among persons aged 1--18 years. The disparity between blacks and nonblacks persisted in all four sites, including in Georgia and Maryland, where 41%--43% of the surveillance catchment area residents were black, and in Oregon and Tennessee, where 4%--6% of catchment area residents were black. The adjusted incidence ratio comparing incidence in blacks with nonblacks ranged from 2.1 (95% CI: 1.2--3.5) in Oregon and Maryland (95% CI: 1.4--3.2) to 2.4 (95% CI: 1.6--3.7) in Georgia.

![Crude annual candidemia incidence,\* by race --- four sites,^†^ United States, 2012--2016\
\* Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years.\
^†^ Georgia, Maryland, Oregon, and Tennessee.](ss6808a1-f4){#F4}

The univariable negative binomial regression estimate of the trend in incidence over the 5-year surveillance period showed no statistically significant change in incidence. No statistically significant trend in incidence over the 5-year period was found by site, age group, sex, or race (Supplementary Table, <https://stacks.cdc.gov/view/cdc/80192>).

Underlying Conditions and Risk Factors for Candidemia
-----------------------------------------------------

One third (33%) of candidemia cases were in patients with diabetes, and 17% were in patients with solid-organ malignancy. Seventeen percent were in patients with liver disease, most commonly hepatitis C virus infection (10%). Sixteen percent were in patients with chronic renal disease, and 12% were in patients who had received hemodialysis in the 90 days before the candidemia diagnosis. Three percent of cases were in patients who were infected with human immunodeficiency virus or had acquired immunodeficiency syndrome ([Table 2](#T2){ref-type="table"}).

###### Underlying conditions and risk factors for candidemia cases --- four sites, United States, 2012--2016

  Underlying condition or risk factor                                                 Georgia      Maryland   Oregon     Tennessee   Total
  ----------------------------------------------------------------------------------- ------------ ---------- ---------- ----------- ----------------
  Diabetes                                                                            556 (34)     372 (36)   85 (25)    139 (28)    **1,152 (33)**
  Solid organ malignancy                                                              277 (17)     194 (19)   42 (12)    83 (17)     **596 (17)**
  Leukemia/lymphoma                                                                   80 (5)       55 (5)     16 (5)     19 (4)      **170 (5)**
  Any liver disease                                                                   172 (11)     254 (25)   72 (21)    92 (18)     **590 (17)**
  Hepatitis C                                                                         66 (4)       165 (16)   54 (16)    67 (13)     **352 (10)**
  Chronic renal disease                                                               306 (19)     199 (19)   23 (7)     30 (6)      **558 (16)**
  Hemodialysis in the 90 days before candidemia diagnosis                             250 (15)     142 (14)   18 (5)     24 (5)      **434 (12)**
  HIV/AIDS                                                                            46 (3)       41 (4)     4 (1)      2 (0)       **93 (3)**
  Injection drug use\* in the last 12 months                                          29 (3)       68 (11)    59 (28)    45 (14)     **201 (10)**
  Any surgery in the 90 days before candidemia diagnosis                              557 (34)     418 (41)   73 (21)    115 (23)    **1,163 (33)**
  Abdominal surgery                                                                   339 (21)     233 (23)   49 (14)    59 (12)     **680 (19)**
  Solid organ or stem cell transplant                                                 37 (2)       36 (4)     3 (1)      2 (0)       **78 (2)**
  Neutropenia in the 2 days before candidemia diagnosis                               59 (4)       47 (5)     21 (6)     9 (2)       **136 (4)**
  Pancreatitis in the 90 days before candidemia diagnosis                             43 (3)       59 (6)     6 (2)      21 (4)      **129 (4)**
  Inflammatory bowel disease                                                          20 (1)       14 (1)     3 (1)      1 (0)       **38 (1)**
  Systemic antibiotics in the 14 days before candidemia diagnosis                     1,268 (78)   855 (84)   235 (68)   340 (68)    **2,698 (77)**
  Total parenteral nutrition in the 14 days before candidemia diagnosis               506 (31)     182 (18)   58 (17)    87 (17)     **833 (24)**
  Central venous catheter in the 2 days before candidemia diagnosis                   1,251 (77)   760 (74)   206 (60)   333 (67)    **2,550 (73)**
  Previous hospitalization in the 90 days before candidemia diagnosis                 950 (58)     591 (58)   192 (56)   275 (55)    **2,008 (58)**
  Intensive care unit admission in the 14 days before or after candidemia diagnosis   953 (59)     640 (63)   139 (40)   211 (42)    **1,943 (56)**
  Resident of a nursing home before hospital admission for candidemia                 208 (13)     217 (21)   27 (8)     42 (8)      **494 (14)**

**Abbreviations:** AIDS = acquired immunodeficiency syndrome; HIV = human immunodeficiency virus.

\* Data for this variable were not collected during 2012--2013. Numbers and percentages are for 2014--2016.

Approximately one third (33%) of cases were in patients who had a surgical procedure in the 90 days before the candidemia diagnosis; abdominal surgery (19%) was the most common type of surgery. Four percent of cases were in patients who had neutropenia in the 2 days before diagnosis. Most (77%) of cases were in patients who had received systemic antibiotics in the 14 days before diagnosis. Almost one fourth (24%) of cases were in patients who had received TPN in the 14 days before the candidemia diagnosis. Georgia had a higher proportion of cases in patients receiving TPN (31%) than other sites (17%--18%). Nearly three fourths (73%) of cases were in patients who had a CVC in place within 2 days before diagnosis. More than half (58%) of cases were in patients who had had a previous hospitalization in the 90 days before the diagnosis, and 96% were in patients who were hospitalized at the time of or in the week after the diagnosis. More than half (56%) of the cases were in patients who were in the ICU in the 14 days before or after the candidemia diagnosis ([Table 2](#T2){ref-type="table"}).

Ten percent of cases were in patients who had used injection drugs in the previous 12 months. The proportion of cases related to injection drug use (IDU) was higher in Oregon (28%) and Tennessee (14%) than in other sites (3% in Georgia and 11% in Maryland) ([Table 2](#T2){ref-type="table"}).

Case Classification
-------------------

Sixty percent of the cases were health care--onset infections, 32% were health care--associated community-onset infections, and 8% were community-onset infections ([Table 3](#T3){ref-type="table"}). Oregon and Tennessee had a higher proportion of community-onset cases (13%--16%) compared with Georgia and Maryland (4%--7%). The median time from admission to initial candidemia culture was 5 days (IQR: 0--16 days). The median hospital stay was 18 days (IQR: 9--35 days).

###### Classification of candidemia cases, current hospitalizations, days from admission to culture, and days of hospitalization --- four sites, United States, 2012--2016

  Characteristics                                 Georgia            Maryland           Oregon             Tennessee          Total
  ----------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------
  **Case classification**                         **No. (%)**        **No. (%)**        **No. (%)**        **No. (%)**        **No. (%)**
  Health care onset\*                             1,064 (65)         622 (61)           170 (49)           251 (50)           **2,107 (60)**
  Health care associated community onset^†^       451 (28)           358 (35)           121 (35)           183 (37)           **1,113 (32)**
  Community onset^§^                              112 (7)            42 (4)             54 (16)            64 (13)            **272 (8)**
  **Current hospitalization for candidemia**      1,556 (96)         997 (98)           324 (94)           458 (92)           **3,335 (96)**
  **Days until culture and of hospitalization**   **Median (IQR)**   **Median (IQR)**   **Median (IQR)**   **Median (IQR)**   **Median (IQR)**
  Days from admission to culture                  8 (1--19)          5 (0--15)          2 (0--9.5)         2 (0--11)          **5 (0--16)**
  Days of hospitalization                         22 (11--43)        17 (8--33)         11 (6--24.5)       12 (6--23)         **18 (9--35)**

**Abbreviation:** IQR = interquartile range.

\* Initial culture positive for *Candida* was obtained ≥3 days after admission.

^†^ Culture positive for *Candida* was obtained \<3 days before admission for a patient with a recent health care exposure.

^§^ Culture positive for *Candida* was obtained \<3 days before admission for a patient without a recent health care exposure.

Previous Candidemia and Previous Antifungal Treatment
-----------------------------------------------------

Nine percent of cases occurred in patients who had a previous episode of candidemia, and the median time from previous to current candidemia episode in the same patient was 104 days (IQR: 56--253 days) ([Table 4](#T4){ref-type="table"}). Forty-one patients had at least three cases each of candidemia, 15 patients had at least four cases, seven patients had at least five cases, and three patients had up to six cases of candidemia. Twelve percent had received antifungal treatment in the 14 days before the candidemia diagnosis; fluconazole was the most common antifungal received before diagnosis (7%), followed by echinocandins (4%) ([Table 4](#T4){ref-type="table"}).

###### Treatment for and outcomes of patients with candidemia cases --- four sites, United States, 2012--2016

  Treatment and outcome                                            Georgia            Maryland           Oregon             Tennessee           Total
  ---------------------------------------------------------------- ------------------ ------------------ ------------------ ------------------- ------------------
  **Treatment**                                                    **No. (%)**        **No. (%)**        **No. (%)**        **No. (%)**         **No. (%)**
  Previous antifungal treatment in the 14 days before candidemia   236 (15)           119 (12)           25 (7)             44 (9)              **424 (12)**
      Fluconazole                                                  160 (10)           58 (6)             5 (1)              33 (7)              **256 (7)**
      Echinocandins                                                77 (5)             45 (4)             1 (0)              6 (1)               **129 (4)**
      Amphotericin B                                               3 (0)              5 (0)              0 (0)              0 (0)               **8 (0)**
      Other azoles\*                                               9 (1)              9 (1)              0 (0)              0 (0)               **18 (1)**
  Previous candidemia                                              153 (9)            123 (12)           16 (5)             27 (5)              **319 (9)**
  Systemic antifungal therapy for candidemia episode^†^            1,391 (85)         834 (82)           288 (83)           363 (73)            **2,876 (82)**
      Fluconazole                                                  972 (60)           505 (49)           206 (60)           256 (51)            **1,939 (56)**
      Echinocandins                                                888 (55)           582 (57)           137 (40)           191 (38)            **1,798 (51)**
      Amphotericin B                                               95 (6)             54 (5)             15 (4)             9 (2)               **173 (5)**
      Other azoles\*                                               25 (2)             35 (3)             9 (3)              6 (1)               **75 (2)**
  **Outcome**                                                                                                                                   
  Death 48 hours after positive *Candida* culture obtained         118 (7)            87 (9)             28 (8)             56 (11)             **289 (8)**
  All-cause in-hospital case-fatality ratio                        394 (24)           280 (27)           69 (20)            130 (26)            **873 (25)**
  Median days from positive *Candida* culture to death             **Median (IQR)**   **Median (IQR)**   **Median (IQR)**   **Median (IQR)**    **Median (IQR)**
  6 (2--14)                                                        6 (2--14)          4 (2--13)          4 (1--11)          **6 (2**--**14)**   

**Abbreviation:** IQR = interquartile range.

\* Including itraconazole, posaconazole, and voriconazole.

^†^ Treatment with each class of antifungal was not mutually exclusive. Treatment might have included more than one class of antifungal.

Antifungal Treatment
--------------------

A total of 82% of 3,492 cases were treated with an antifungal for candidemia. The most common antifungal received was fluconazole (56%), followed by echinocandins (51%) ([Table 4](#T4){ref-type="table"}). Among cases in adults who were treated, 34% were treated with fluconazole alone and 30% with echinocandins alone; 34% received both fluconazole and echinocandins. Use of echinocandins increased over time (48% in 2012 to 55% in 2016) whereas the use of fluconazole decreased over time (57% in 2012 to 49% in 2016). Echinocandins were used more frequently in the Georgia and Maryland sites (55%--57% of cases) than in the Oregon and Tennessee sites (38%--40% of cases). Amphotericin B was primarily used to treat cases among children, with 67% of cases in infants (aged \<1 year) and 31% of cases in children aged 1--18 years receiving this drug for treatment of candidemia. Of the 19% of cases in patients not receiving antifungal treatment, 33% were in patients who died within 48 hours of culture, and another 7% were in patients who were discharged to palliative care. An additional 20% were in patients who were not hospitalized or had an unknown hospitalization status, and 11% were in patients discharged before culture result was available; therefore, receipt of antifungal treatment could not be determined.

Deaths
------

The all-cause in-hospital case-fatality ratio was 25% for any time after admission and 8% for \<48 hours after a positive culture. The all-cause in-hospital case-fatality ratio varied by age group: 15% in infants (aged \<1 year), 10% in persons aged 1--18 years, 15% in adults aged 19--44 years, 26% in adults aged 45--64 years, and 32% in adults aged ≥65 years. The median time from positive candidemia culture to death was 6 days (IQR: 2--14) ([Table 4](#T4){ref-type="table"}).

Species Distribution
--------------------

*C. albicans* accounted for 39% of cases, and other *Candida* species accounted for 61%; the most common species were *C. glabrata* (28%), *C. parapsilosis* (15%), and *Candida tropicalis* (9%). Four percent of cases involved multiple *Candida* species isolated on the date of the initial candidemia blood culture or in the 30 days after. The lowest proportion of *C. albicans* was in Maryland (35%), compared with 40%--42% in the other three sites ([Figure 5](#F5){ref-type="fig"}; [Table 5](#T5){ref-type="table"}).

![Species\* distribution of *Candida* organisms, by year --- four sites,^†^ United States, 2012--2016\
\* The category "Candida, other species" includes *C. allocifferrii, C. bracarensis, C. dubliniensis, C. fermentati, C. guilliermondii, C. kefyr, C. krusei, C. lipolytica, C. lusitaniae, C. metapsilosis, C. orthopsilosis, C. pararugosa, C. pelliculosa, C. rugosa,* and *C. sojae*.\
^†^ Georgia, Maryland, Oregon, and Tennessee.](ss6808a1-f5){#F5}

###### Species distribution of candidemia cases --- four sites, United States, 2012--2016

  *Candida* species             Georgia    Maryland   Oregon     Tennessee   Total
  ----------------------------- ---------- ---------- ---------- ----------- ----------------
  *C. albicans*                 636 (40)   338 (35)   129 (40)   204 (42)    **1,307 (39)**
  *C. glabrata*                 408 (26)   309 (32)   85 (26)    147 (31)    **949 (28)**
  *C. tropicalis*               120 (8)    107 (11)   17 (5)     48 (10)     **292 (9)**
  *C. parapsilosis*             271 (17)   123 (13)   59 (18)    43 (9)      **496 (15)**
  *C. dubliniensis*             30 (2)     44 (5)     9 (3)      18 (4)      **101 (3)**
  *C. guilliermondii*           7 (0)      3 (0)      8 (3)      0 (0)       **18 (1)**
  *C. lusitaniae*               41 (3)     12 (1)     2 (1)      11 (2)      **66 (2)**
  *C. krusei*                   36 (2)     23 (2)     9 (3)      4 (1)       **72 (2)**
  *Candida*, other species\*    30 (2)     10 (1)     6 (2)      7 (1)       **53 (2)**
  *Candida*, multiple species   47 (3)     53 (5)     20 (5)     16 (3)      **136 (4)**

\* Includes *C. allocifferrii, C. bracarensis, C. fermentati, C. kefyr, C. lipolytica, C. metapsilosis, C. orthopsilosis, C. pararugosa, C. pelliculosa, C. rugosa,* and *C. sojae.*

Antifungal Resistance
---------------------

Seven percent of the 2,997 isolates analyzed for antifungal resistance had either acquired or intrinsic resistance to fluconazole, and 1.6% were resistant to echinocandins. Fluconazole resistance was 8.6% among *C. glabrata* isolates, 7.7% among *C. parapsilosis* isolates, and 4.2% among *C. tropicalis* isolates ([Table 6](#T6){ref-type="table"}). Resistance to fluconazole increased from 4.4% in 2012 to 14% in 2016 among *C. parapsilosis* isolates, and no substantial increases occurred in fluconazole resistance in other species. Resistance to echinocandins varied by year for *C. glabrata* (2.1%--8.2%) and *C. albicans* (0%--0.9%). None of the *C. parapsilosis* isolates were echinocandin resistant. Multidrug resistance (i.e., resistance to two or more drug classes) was identified in 1.3% of *C. glabrata* isolates. Fluconazole resistance ranged from 5.9% to 10.3% in Georgia, 4.0% to 10.8% in Maryland, 0% to 9.6% in Oregon, and 1.6% to 8.6% in Tennessee ([Table 7](#T7){ref-type="table"}). Echinocandin resistance ranged from 0.4% to 4.3% in Georgia, 0.5% to 3.5% in Maryland, 0% to 1.9% in Oregon, and 0% to 2.1% in Tennessee. Multidrug resistance was only found in isolates from Georgia (0%--1.6%) and Maryland (0%--1.5%).

###### Drug resistance among *Candida* isolates,\* by species --- four sites,^†^ United States, 2012--2016

  *Candida* species and drug   2012          2013          2014          2015          2016          Total
  ---------------------------- ------------- ------------- ------------- ------------- ------------- ---------------
  ***C. albicans***            **N = 268**   **N = 217**   **N = 267**   **N = 246**   **N = 235**   **N = 1,233**
  Amphotericin B               0             0             0             0             0             0
  Fluconazole                  1 (0.4)       1 (0.5)       0             2 (0.8)       0             4 (0.3)
  Voriconazole                 0             0             0             1 (0.4)       0             1 (0.1)
  Echinocandins^§^             0             2 (0.9)       0             2 (0.8)       1 (0.4)       5 (0.4)
  Multiple drugs^¶^            0             0             0             0             0             0
  ***C. glabrata***            **N = 205**   **N = 184**   **N = 182**   **N = 190**   **N = 168**   **N = 929**
  Amphotericin B               0             0             0             0             0             0
  Fluconazole                  21 (10.2)     13 (7.1)      15 (8.2)      13 (6.8)      18 (10.7)     80 (8.6)
  Voriconazole                 ---\*\*       ---           ---           ---           ---           ---
  Echinocandins^§^             10 (4.9)      15 (8.2)      6 (3.3)       4 (2.1)       6 (3.6)       41 (4.4)
  Multiple drugs^¶^            3 (1.5)       5 (2.7)       2 (1.1)       2 (1.1)       0             12 (1.3)
  ***C. krusei***              **N = 17**    **N = 12**    **N = 14**    **N = 18**    **N = 16**    **N = 77**
  Amphotericin B               0             0             0             0             0             0
  Fluconazole                  ---           ---           ---           ---           ---           ---
  Voriconazole                 0             0             0             0             0             0
  Echinocandins^§^             0             2 (16.7)      0             0             0             2 (2.6)
  Multiple drugs^¶^            0             2 (16.7)      0             0             0             2 (2.6)
  ***C. parapsilosis***        **N = 91**    **N = 93**    **N = 108**   **N = 84**    **N = 93**    **N = 469**
  Amphotericin B               0             0             0             0             0             0
  Fluconazole                  4 (4.4)       4 (4.3)       5 (4.6)       10 (11.9)     13 (14.0)     36 (7.7)
  Voriconazole                 0             2 (2.2)       1 (0.9)       3 (3.6)       4 (4.3)       10 (2.1)
  Echinocandins^§^             0             0             0             0             0             0
  Multiple drugs^¶^            0             0             0             0             0             0
  ***C. tropicalis***          **N = 52**    **N = 59**    **N = 63**    **N = 56**    **N = 59**    **N = 289**
  Amphotericin B               0             0             0             0             0             0
  Fluconazole                  3 (5.8)       1 (1.7)       5 (7.9)       1 (1.8)       2 (3.4)       12 (4.2)
  Voriconazole                 1 (1.9)       1 (1.7)       2 (3.2)       0             2 (3.4)       6 (2.1)
  Echinocandins^§^             0             0             0             0             0             0
  Multiple drugs^¶^            0             0             0             0             0             0

\* Only includes isolates sent to CDC.

^†^ Georgia, Maryland, Oregon, and Tennessee.

^§^ Defined resistant to echinocandins if an isolate was resistant to any of the echinocandins.

^¶^ Isolates were tested for resistance to any echinocandin and fluconazole.

\*\* No breakpoints.

###### Drug resistance in *Candida* isolates,\* by site --- four sites, United States, 2012--2016

  Site and drug      2012          2013          2014          2015          2016
  ------------------ ------------- ------------- ------------- ------------- -------------
  **Georgia**        **N = 306**   **N = 253**   **N = 270**   **N = 240**   **N = 232**
  Amphotericin B     0             0             0             0             0
  Fluconazole        26 (8.5)      17 (6.7)      16 (5.9)      20 (8.3)      24 (10.3)
  Voriconazole       1 (0.3)       1 (0.4)       2 (0.7)       0             1 (0.4)
  Echinocandins^†^   6 (2.0)       11 (4.3)      5 (1.9)       1 (0.4)       3 (1.3)
  Multidrug^§^       3 (1.0)       4 (1.6)       2 (0.7)       0             0
  **Maryland**       **N = 186**   **N = 198**   **N = 214**   **N = 203**   **N = 177**
  Amphotericin B     0             0             0             0             0
  Fluconazole        10 (5.4)      8 (4.0)       16 (7.5)      22 (10.8)     19 (10.7)
  Voriconazole       0             1 (0.5)       0             3 (1.5)       3 (1.7)
  Echinocandins^†^   4 (2.2)       7 (3.5)       1 (0.5)       3 (1.5)       3 (1.7)
  Multidrug^§^       0             3 (1.5)       0             2 (1.0)       0
  **Oregon**         **N = 60**    **N = 52**    **N = 72**    **N = 54**    **N = 60**
  Amphotericin B     0             0             0             0             0
  Fluconazole        3 (5.0)       5 (9.6)       3 (4.2)       0             2 (3.3)
  Voriconazole       0             1 (1.9)       0             0             0
  Echinocandins^†^   0             1 (1.9)       0             0             0
  Multidrug^§^       0             0             0             0             0
  **Tennessee**      **N = 81**    **N = 62**    **N = 78**    **N = 97**    **N = 102**
  Amphotericin B     0             0             0             0             0
  Fluconazole        7 (8.6)       1 (1.6)       4 (5.1)       2 (2.1)       4 (3.9)
  Voriconazole       0             0             1 (1.3)       1 (1.0)       2 (2.0)
  Echinocandins^†^   0             0             0             2 (2.1)       1 (1.0)
  Multidrug^§^       0             0             0             0             0

\* Only includes isolates sent to CDC.

^†^ Defined resistant to echinocandins if an isolate was resistant to any of the echinocandins.

^§^ Isolates were tested for resistance to any echinocandin and fluconazole.

Discussion
==========

This report summarizes the incidence, underlying conditions, health care exposure, treatment, species distribution, antifungal resistance, and outcomes associated with approximately 3,500 candidemia cases at four CDC EIP surveillance sites during 2012--2016. The crude candidemia incidence averaged across sites and years was 8.7 per 100,000 population, and the all-cause in-hospital case-fatality ratio was 25%.

Candidemia incidence was highest in the Maryland site and lowest in the Oregon site. These rates differed significantly even after adjusting for year, race, age, and sex, suggesting that the difference cannot be fully explained by demographic characteristics over time. Unlike other pathogenic fungi, such as *Coccidioides* and *Histoplasma* species, which are more prevalent in the environment in specific geographic parts of the United States and hence result in varying incidence geographically ([@R38],[@R39]), *Candida* is believed to be commensal in the human host. Regional differences in colonization with *Candida* in the United States have not been studied. Site-specific differences in the incidence of candidemia might be due to differences in the percentages of patients with underlying conditions such as diabetes and other immunosuppressive conditions ([@R40],[@R41]), differences in practice patterns and use of antibiotics, and differences in use of antifungals and CVCs, all of which contribute to the risk for candidemia.

Candidemia incidence continues to be highest in adults aged ≥65 years, followed by infants aged \<1 year. This contrasts with data from the early 1990s, when infants had the highest incidence ([@R6]), followed by substantial decreases by the late 2000s ([@R26],[@R28]). Enhanced infection control practices, including appropriate catheter use to limit catheter-related bloodstream infections ([@R42]--[@R44]), antibiotic stewardship, and antifungal prophylaxis practices, might be responsible for some of the decreases. However, as the population of patients at risk for candidemia, such as adults aged ≥65 years or persons who are immunosuppressed, increases ([@R45]), other strategies to prevent candidemia in health care settings might be needed.

Candidemia incidence was higher in males than females even after adjusting for demographic factors, and this difference persisted across all adult age and race groups. Although females have more noninvasive candidiasis (primarily vaginal candidiasis) than males, invasive bloodstream infections were less common among females than among males. Although the reasons for differences in candidemia incidence by sex are unknown, these differences have been found with other fungal diseases such as paracoccidioidomycosis and coccidioidomycosis. For paracoccidioidomycosis, the differences in incidence occur in postpubertal age groups (approximately aged ≥12 years), and laboratory research has shown that estrogen levels might have a role in acquisition of fungal diseases ([@R46],[@R47]). Whether estrogen levels or other factors play a role in differences in risk for candidemia among females and males is not well understood.

The previously reported racial disparity in candidemia persisted in this surveillance period ([@R6]), with a 2.3 times higher incidence among blacks than among nonblacks. This disparity was found in all surveillance sites, even though the sites had markedly different underlying population demographics (i.e., Georgia and Maryland sites, where approximately 40% of the populations in the counties under surveillance was black, compared with \<10% in the Oregon and Tennessee sites \[[@R37]\]). In addition, racial disparities existed in almost all age groups. Socioeconomic factors might be a proxy for race differences and could play a role in candidemia incidence disparities ([@R48],[@R49]). A study exploring nosocomial infections such as invasive methicillin-resistant *Staphylococcus aureus* (MRSA) infection found that racial disparity could partially be explained by socioeconomic factors such as overcrowding and limited access and availability to health care services ([@R50]). Differences also might exist because blacks have higher rates of diabetes, hemodialysis, and liver diseases ([@R51]), which are risk factors for candidemia ([@R52]). Additional research on the influence of race and socioeconomic factors on disparities in candidemia infections is warranted.

Known risk factors for candidemia, including diabetes, malignancies, liver and renal disease, and recent surgery, continue to be frequent among patients with candidemia. As expected, a high proportion of cases were in patients with CVCs and who received antibiotics and TPN. Although neutropenia ([@R53],[@R54]), hematologic malignancies ([@R53]), and bone marrow transplants ([@R10],[@R13]) are well-recognized risk factors for candidemia, only a small proportion (\<5%) of cases were in patients with these underlying conditions. This might be due to increasing use of antifungal prophylactic regimens among patients with leukemia or lymphoma, patients who received bone marrow transplants, and chemotherapy recipients ([@R15]).

The finding that 10% of cases were in patients who had used injection drugs in the previous 12 months was surprising because candidemia is generally considered a health care--associated infection. Although the association between IDU and candidemia is known, IDU is not thought to be a very common contributing factor to candidemia risk. The proportion of candidemia patients with an IDU history is much higher than the estimated \<1% of the entire U.S. population with a history of IDU during the previous 12 months ([@R55]), suggesting that those who inject drugs are at much higher risk for candidemia than the general population. Recent literature suggests IDU might be an increasingly common risk factor for candidemia ([@R56]). The growing opioid crisis in the United States ([@R57],[@R58]) might be contributing to increased rates of IDU and their infectious disease sequelae ([@R59]). Ongoing surveillance should closely monitor trends in IDU and assess this type of drug use as an emerging risk factor for *Candida* infection and other acute infections.

Drug-resistant *Candida* species infections are a serious public health concern and were included in CDC's 2013 Antibiotic Resistance Threat Report ([@R60]). *Candida* species other than *C. albicans*, which tend to be more drug resistant than *C. albicans*, accounted for 61% of isolates in the surveillance program, similar to what has been reported previously ([@R6]). Fluconazole resistance was fairly common in *C. glabrata* isolates; one in 10 isolates was resistant to fluconazole. Echinocandin resistance among *C. glabrata* isolates was low when taken as a whole across the surveillance program. However, as reported in a previous publication using EIP surveillance data, resistance tends to be concentrated in a few tertiary care hospitals that care for high-acuity patients with malignancies and transplants; three hospitals out of 80 included in the candidemia EIP surveillance accounted for more than half of all echinocandin-resistant isolates ([@R19]). Although a concern for echinocandin resistance in *C. parapsilosis* exists because of a naturally occurring variation in the protein target for echinocandins ([@R61]), no echinocandin resistance was identified among *C. parapsilosis* isolates in this surveillance program. Nevertheless, increasing fluconazole resistance was noted among *C. parapsilosis* isolates. Clinicians who treat patients with candidemia should strongly consider obtaining antifungal susceptibility testing (AFST) and be aware of local antifungal resistance patterns when making treatment decisions.

Species-level identification and AFST are important aspects of candidemia management. However, availability of both types of testing, especially AFST, is limited in clinical laboratories ([@R62]). Availability is improving through expansion of new types of species identification methods such as MALDI-TOF and the establishment of CDC's Antibiotic Resistance Laboratory Network ([@R63]), which conducts fungal species identification and tests for antifungal susceptibility.

In contrast with the 2009 Infectious Disease Society of America guidelines for the treatment of invasive candidiasis, in which echinocandins were recommended only for neutropenic patients and patients with previous exposure to antifungals ([@R64]), the 2016 guidelines recommend echinocandins as the initial therapy for treatment of most types of invasive candidiasis among adults ([@R43]). The change in recommendations was based on the increasing frequency of infections caused by species other than *C. albicans*, increasing levels of fluconazole resistance, and evidence that echinocandins are more effective. Echinocandin use before 2016 increased, and changes in practice can sometimes precede updates in guidelines. As echinocandins are used with greater frequency, continuing to monitor both trends in treatment patterns as well as resistance to echinocandins is important. Resistance to echinocandins will be problematic because of the limited antifungal armamentarium. Limited alternatives that do exist (such as amphotericin B) have substantial toxicity ([@R65]). Health care facilities should consider assessing antifungal use as part of antimicrobial stewardship programs to help preserve treatment options for the future.

Although cases of *C. auris* were not detected in the surveillance sites during 2012--2016, ongoing transmission of *C. auris* has been detected in several areas in the United States, primarily in Illinois, New Jersey, and New York ([@R66]), posing an emerging threat in the United States and worldwide because of high-level antifungal resistance and spread in health care facilities ([@R67]--[@R69]). As of July 2019, approximately 700 clinical cases of *C. auris* had been documented in the United States ([@R22]). Infections with other rare and drug-resistant *Candida* species, including *Candida haemulonii*, *Candida duobushaemulonii*, and *Candida rugosa*, have been reported from surveillance in other countries ([@R70],[@R71]). Ongoing surveillance for infections caused by *Candida* species will be critical in detecting rare and emerging drug-resistant species in the United States before they become widespread.

Limitations
===========

The findings in this report are subject to at least four limitations. First, underlying conditions and predisposing factors described in this report were extracted from medical charts, which might have resulted in underestimates of certain conditions, such as IDU, which might not be systematically recorded on medical charts. Second, although the surveillance was active, population based, and frequently audited, certain culture-proven cases might have been missed, likely underestimating the number of infections. In addition, this surveillance underestimates the true proportion of invasive candidiasis because it only includes cases positive by blood culture, which has suboptimal sensitivity, particularly for intraabdominal candidiasis, or infections in which blood cultures were not obtained. Third, surveillance data were available from 22 counties in four states representing 2.5% of the U.S. population and therefore are not nationally representative. Finally, only five time points were assessed, which limits the ability to understand long-term trends. Nevertheless, data presented in this report describe surveillance information on geographically and demographically diverse populations and are the largest data source of population-based candidemia incidence data in the United States.

Conclusion
==========

Candidemia remains a serious cause of illness and death in the United States, and surveillance data are necessary to focus prevention efforts. Active surveillance for candidemia should continue to monitor incidence trends by age and race, track emergence of resistance and species distribution, monitor changes in underlying conditions and predisposing factors, and assess trends in antifungal treatment and outcomes. Surveillance was expanded to nine sites in 2017, and ongoing surveillance efforts are expected to improve the development of treatment and prevention efforts.
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